SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members discuss its potential, particularly in relation to Bitcoin's ecosystem and meme coin popularity. Some investors are excited about its prospects, while others express concerns about price predictions and potential manipulation. The conversations also touch upon its availability on certain exchanges and comparisons to other meme coins like Doge.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending amid excitement surrounding an upcoming airdrop of QKitty and Broke tokens to NFT holders and Brokecoin holders. The community is rallying around the project's increasing accessibility through CEX listings and upcoming staking features.  Enthusiasm is high as the community focuses on growing the number of watchers and a potential token burn.

Brewski

$BREWSKI.X is trending as the community rallies around a patriotic, beer-themed meme coin. Increased watcher counts and mentions of 'whale activity' are fueling speculation about a potential surge. The coin is being associated with symbols of American identity and a 'for the boys' mentality, contributing to its visibility.

Merging the worlds of decentralized computation and gaming to scale compute while you have a blast!  $GMRX: A token for our entire economy and our fully-built, plug-and-play cloud computing, games distribution and gamer experiences platform.  Decentralized computation:  1. Targeting the 1.6 billion desktop gamers globally.  2. Biggest active decentralized GPU sharing network.  3. Automatic GPU monetization (AI, Render & Mining Jobs).  Gaming:  1. We own Gaimin Gladiators, one of the top esports organizations in the world.  2. Integrated web2 and web3 gaming platform with NFT functionality and in-app marketplace.

Gaimin

Gaimin ($GMRX.X) is trending as the community discusses its platform downloads, user base, and potential utility. The upcoming release of 'PRO,' which reportedly offers the highest mining payouts, is also a key talking point. Some users are expressing bullish sentiment, while others remain skeptical.

Kaspa is a proof-of-work cryptocurrency which implements the GHOSTDAG protocol. Unlike traditional blockchains, GHOSTDAG does not orphan blocks created in parallel, rather allows them to coexist and orders them in consensus. Whereby our blockchain is actually a blockDAG; you can see GHOSTDAG in action in a real time blockDAG visualizer). This generalization of Nakamoto consensus allows for secure operation while maintaining very high block rates (currently one block per second, aiming for 10/sec, dreaming of 100/sec) and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as the community discusses the recent Crescendo upgrade and the potential impact of upcoming smart contracts. Despite some bearish sentiment and concerns about exchange listings, many holders remain optimistic about Kaspa's technology and long-term potential, viewing the current price as a buying opportunity. Discussions also include the broader implications of Kaspa's technology in the crypto space.

USD1 is the native stablecoin of the Kinesis ecosystem, pegged 1:1 to the US dollar. Built on the Stellar and ERC-20 blockchains, it offers secure, fast, and low-cost transactions. Fully backed by over $15 billion in high-quality reserves, USD1 provides institutional-grade security, transparency with monthly attestations, and seamless integration within the Kinesis platform.  Check out the official website to learn more: https://kinesis.money/pro/usd1/

USD One

USD1.X is trending as the crypto community discusses its potential as a competitor to established stablecoins and its role in bridging traditional finance with DeFi. Community members are focused on adoption, tokenomics, and potential integration with traditional banking. The connection to WLFI and the Trump family is also fueling interest and debate.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Shares of GYRO are trending as the company's plan to sell a parcel of land is expected to significantly increase its NAV, sparking interest in its undervalued market cap. Community members are noting the stock's low float, anticipating a potential breakout, with some eyeing a move towards previous price levels. Traders are also discussing technical indicators, suggesting a possible squeeze.

Numeraire

Numeraire is trending as traders discuss its potential, referencing its low circulating supply and AI narrative. Community members are pointing to technical indicators, anticipating a breakout and potential run to higher price targets. The recent surge and consolidation patterns are also being actively discussed.

DeFiChain is a decentralized blockchain platform dedicated to enable fast, intelligent, and transparent decentralized financial services.  Unlike most of the other DeFi projects that are built on the Ethereum network, DeFiChain is built on bitcoin (as a software fork), and is anchored to the bitcoin blockchain (via merkle root) every few minutes for maximum security   DeFiChain is designed to be non-Turing complete to reduce smart contract errors (extremely important for finance transactions) and its op codes only allow run decentralized finance dapps.  This ensures that only financial transactions are possible, instead of having games and casinos clogging the ecosystem and causing high transaction fees.  Upcoming features of the DeFiChain include Decentralized: Lending, Wrapping of Tokens, Pricing Oracles, Exchanges, Transferable Debts and Receivables, Non-Collateralized Debt, Asset Tokenization, Distribution of Dividends, and YIELD FARMING!

DeFiChain

DeFiChain ($DFI.X) is trending as community members highlight its development activity and potential within the decentralized finance space, particularly its connection to Bitcoin. Bullish sentiment is fueled by its perceived undervaluation and potential for significant gains, with some suggesting it could reach previous all-time highs. Community members are actively discussing its use case in decentralized finance paired with Bitcoin.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as the community discusses its potential as the next big Real World Asset (RWA) coin. Investors are excited about its early stage and are speculating about significant market cap growth, while also inquiring about where to purchase it. Some users are reporting issues sending the coin to a ledger wallet.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? 

Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition. 

Zacks Investment Ideas feature highlights: Church & Dwight, Eli Lilly and Viatris

CEOs at Church & Dwight, Eli Lilly, and Viatris are buying shares after stock pullbacks, signaling insider confidence.

Insider Watch: 3 CEOs Buying the Dip

Large-cap stocks CHD, LLY, and VTRS have seen their respective CEOs make purchases over the last month. What do they see?

Zacks Investment Ideas feature highlights: Eli Lilly, Eaton and Interactive Brokers

Eli Lilly, Eaton, and Interactive Brokers post standout Q2 results, with booming sales, raised guidance, and record-breaking growth.

Chinese pharmaceutical companies that once supplied ingredients for more than a billion makeshift doses of weight-loss drugs in the U.S. are apparently shifting their focus to generics as regulators crack down on compounded copies of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.Over the past two years, at least eight Chinese firms,&nbsp; including Jiangsu Sinopep-Allsino Biopharmaceutical and Hybio Pharmaceutical, shipped raw semaglutide and tirzepatide to the U.S., according to Reuters’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinese-companies-turn-generics-shipments-behind-us-weight-loss-craze-fade-2025-09-02/">report</a>, citing FDA shipping data and public records.&nbsp;Sinopep and Hybio are now reportedly working to develop generic semaglutide, while Nanjing Hanxin Pharmaceutical and Fujian Genohope Biotech may follow.&nbsp;With U.S. law now restricting compounders to personalized doses or formulations not otherwise available, Chinese suppliers are eyeing markets where Novo’s key semaglutide patent is set to expire in 2026, including Canada and Brazil.&nbsp;However, producing semaglutide in&nbsp;its final injectable form is complex, and branded drugmakers could delay generic launches, according to a lawyer for a generic drugmaker.The regulatory shift has already choked supply. In the second quarter of 2025, U.S.-bound&nbsp;shipments of semaglutide and tirzepatide declined by approximately 90% and 34%,&nbsp;respectively, compared to the same quarter a year earlier. That marked a sharp reversal from 2024, when Chinese companies shipped enough semaglutide to make more than one billion starter doses.&nbsp;Novo told the U.S. Commerce Department that in just six months, Chinese exporters sent enough to make 1.5 billion Wegovy doses.The boom began after the FDA declared shortages in 2022, opening the door for compounding pharmacies, often supported by telehealth firms that grew during the pandemic, to sell cheap copies.&nbsp;Never before had a new drug become so wildly popular that the manufacturer simply couldn’t keep up, said Robert Califf, who has led the FDA twice, calling the compounding surge a “once-in-a-decade” issue.The economics were compelling. A 2024 JAMA report estimated&nbsp;that the production cost of&nbsp;semaglutide powder was only $0.07 per month, while Chinese suppliers could sell it at up to seven times that amount.&nbsp;U.S. compounding pharmacies were then able to offer injections at about $230 a month, which is less than half the price of branded versions.The fallout has been costly for Novo Nordisk, which missed quarterly sales targets and saw its shares cut in half in 2025, contributing to the ouster of its CEO in May.As shipments of semaglutide and tirzepatide dry up, some Chinese companies are shifting toward liraglutide, the active ingredient in older Novo drugs Saxenda and Victoza.&nbsp;Generic versions of liraglutide have been available in the U.S. since 2024 and are now promoted by telehealth sites that once pushed semaglutide. A wholesale supplier told Reuters he has seen demand for liraglutide climb.On Stocktwits, retail sentiment was ‘extremely bearish’ for Novo Nordisk and ‘bearish’ for Eli Lilly, with both seeing ‘extremely low’ message volume.While&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 33.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dropped 4.2% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report

As U.S. restrictions tighten, suppliers are targeting markets such as Canada and Brazil, where patents are set to expire in 2026.

Equity

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know  

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

These 3 Companies are Seeing Supercharged Sales Growth

The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth. 

Viking Therapeutics Loses 20% in a Month: How to Play the Stock

VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales 

Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$6.36	--	--	N/A
Q2 '25	$5.60	$6.31	12.70%	BEAT
Q1 '25	$3.26	$3.34	2.51%	BEAT
Q4 '24	$5.01	$5.32	6.15%	BEAT
Q3 '24	$1.45	$1.18	-18.79%	MISSED

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest LLY News

LLY Lilly(Eli) & Co